Stocks and Investing
Stocks and Investing
Mon, May 10, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, May 7, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Paul Choi Maintained (BBIO) at Strong Buy with Decreased Target to $80 on, May 7th, 2021
Paul Choi of Goldman Sachs, Maintained "BridgeBio Pharma, Inc." (BBIO) at Strong Buy with Decreased Target from $92 to $80 on, May 7th, 2021.
Paul has made no other calls on BBIO in the last 4 months.
There are 3 other peers that have a rating on BBIO. Out of the 3 peers that are also analyzing BBIO, 0 agree with Paul's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Paul
- Mani Foroohar of "SVB Leerink" Maintained at Buy with Increased Target to $75 on, Tuesday, March 23rd, 2021
- Salim Syed of "Mizuho" Maintained at Strong Buy with Increased Target to $86 on, Thursday, March 4th, 2021
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $87 on, Monday, January 11th, 2021
Contributing Sources